Literature DB >> 36002779

Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models II: Practical Application of Tissue Lumping Theories for Pharmacokinetics of Various Compounds.

Yoo-Seong Jeong1, Min-Soo Kim1, Suk-Jae Chung2.   

Abstract

In our companion paper, we described the theoretical basis for tissue lumping in whole-body physiologically based pharmacokinetic (WB-PBPK) models and found that Kdet, a coefficient for determining the number of tissue groups of distinct transit time in WB-PBPK models, was related to the fractional change in the terminal slope (FCT) when tissues were progressively lumped from the longest transit time to shorter ones. This study was conducted to identify the practical threshold of Kdet by applying the lumping theory to plasma/blood concentration-time relationships of 113 model compounds collected from the literature. We found that drugs having Kdet < 0.3 were associated with FCT < 0.1 even when all peripheral tissues were lumped, resulting in comparable plasma concentration-time profiles between one-tissue minimal PBPK (mPBPK) and WB-PBPK models. For drugs with Kdet ≥ 1, WB-PBPK profiles appeared similar with two-tissue mPBPK models by applying the rule of FCT < 0.1 for lumping slowly equilibrating tissues. The two-tissue mPBPK model also appeared appropriate in terms of concentration-time profiles for drugs with 0.3 ≤ Kdet < 1, although, some compounds (15.9% of the total cases), but not all, in this range showed a slight (maximum of 18.9% of the total AUC) deviation from WB-PBPK models, indicating that the two-tissue model, with caution, could still be used for those cases. Comparison of kinetic parameters between traditional (model-fitting) and current (theoretical calculation) mPBPK analyses revealed their significant correlations. Collectively, these observations suggest that the number of tissue groups could be determined based on the Kdet/FCT criteria, and plasma concentration-time profiles from WB-PBPK could be calculated using equations significantly less complex.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  Bottom-up approach; Minimal PBPK; Number of tissue group; Tissue lumping; Whole-body PBPK

Mesh:

Substances:

Year:  2022        PMID: 36002779     DOI: 10.1208/s12248-022-00733-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   3.603


  5 in total

1.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

Authors:  Trudy Rodgers; David Leahy; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

2.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

3.  Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2 cell permeability.

Authors:  Masaaki Fujikawa; Rieko Ano; Kazuya Nakao; Ryo Shimizu; Miki Akamatsu
Journal:  Bioorg Med Chem       Date:  2005-08-01       Impact factor: 3.641

4.  Prediction of human blood-to-plasma drug concentration ratio.

Authors:  Takahide Uchimura; Motohiro Kato; Tomohisa Saito; Haruki Kinoshita
Journal:  Biopharm Drug Dispos       Date:  2010-07       Impact factor: 1.627

5.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.